Completed × Inflammatory Breast Neoplasms × Docetaxel × Clear all Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer
Phase 1/2 Completed
93 enrolled
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
Phase 2 Completed
105 enrolled 17 charts
PEGASE07
Phase 3 Completed
174 enrolled
NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer
Phase 2 Completed
41 enrolled 10 charts
Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer
Phase 1/2 Completed
129 enrolled
Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
Phase 1/2 Completed
53 enrolled
Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer
Phase 3 Completed
1,856 enrolled
Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
Phase 3 Completed
1,500 enrolled
Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer
Phase 2 Completed
45 enrolled